Neuroendocrine Tumor Treatment Market Forecast: What to Expect by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Neuroendocrine Tumor Treatment Market From 2025 To 2034?

The neuroendocrine tumor treatment market has experienced substantial expansion in recent years. Its value is projected to increase from $2.17 billion in 2024 to $2.39 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.4%. Historically, this growth has stemmed from factors such as enhanced clinical research and understanding, improved awareness and education, the development of specialized medical expertise, breakthroughs in radiation therapy, and the availability of comprehensive supportive care services.

The neuroendocrine tumor treatment market is projected to experience swift expansion in the coming years. This market is anticipated to reach $3.59 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.6%. This anticipated growth during the forecast period stems from developments in precision medicine, breakthroughs in immunotherapy, the prevalence of minimally invasive procedures, increasing incidence rates, and the integration of telemedicine and remote care. Key trends identified for the forecast period encompass progress in diagnostic technologies, enhancements in peptide receptor radionuclide therapy (PRRT), the application of nanotechnology in drug delivery, the introduction of novel radiopharmaceuticals, and collaborative efforts across various disciplines.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12248&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Neuroendocrine Tumor Treatment Industry?

The increasing incidence of neuroendocrine tumors is anticipated to fuel the expansion of the neuroendocrine tumor treatment market going forward. Neuroendocrine tumors (NETs) are a rare form of growth that originates from neuroendocrine cells. The treatment for neuroendocrine tumors is a crucial process for managing these conditions, aiming to alleviate symptoms, halt tumor progression, and utilize radiation therapy to destroy tumor cells. For illustration, in March 2023, reports from the American Society of Clinical Oncology (ASCO), a US-based professional organization, indicated that over 12,000 individuals in the US are diagnosed with neuroendocrine tumors annually, with an estimated 171,000 people living with this diagnosis in 2023. Furthermore, in August 2022, Cancer Australia, an Australia-based cancer control agency, stated that 5,437 people were diagnosed with neuroendocrine tumors in Australia during 2022, accounting for 3.4% of all new cases diagnosed that year. Hence, the rising prevalence of neuroendocrine tumors is accelerating the growth of the neuroendocrine tumor treatment market.

What Are The Major Segment Categories Driving The Neuroendocrine Tumor Treatment Market Growth?

The neuroendocrine tumor treatmentmarket covered in this report is segmented –

1) By Product: Somatostatin Analogs (SSAs); Targeted Therapy; Chemotherapy; Others Products

2) By Indication: Lungs; Pancreas; Gastrointestinal; Others Indications

3) By End-Users: Hospitals; Oncology Centers; Other End-Users

Subsegments:

1) By Somatostatin Analogs (SSAs): Octreotide; Lanreotide

2) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Peptide Receptor Radionuclide Therapy (PRRT)

3) By Chemotherapy: Traditional Chemotherapy Agents; Combination Chemotherapy Regimens

4) By Other Products: Immunotherapy; Supportive Care Medications

Which Key Trends Are Expected To Influence The Neuroendocrine Tumor Treatment Market In The Coming Years?

Clinical drug development for therapeutic purposes represents a primary and growing trend within the neuroendocrine tumor treatment market. Major corporations engaged in this market are actively pursuing the creation of innovative treatments to uphold their market presence. For example, in October 2022, Viewpoint Molecular Targeting, Inc., a US-based pharmaceutical entity, declared that the U.S. Food and Drug Administration (FDA), a US federal agency, had awarded fast-track designation for the advancement of [212Pb] VMT-a-NET. This development targets the treatment of patients with SSTR2-positive unresectable or metastatic neuroendocrine tumors (NETs). VMT-a-NET functions as a targeted alpha-particle therapy (TAT), engineered to eliminate cancer cells that specifically express somatostatin receptors. The FDA’s fast-track designation is purposed to accelerate both the development and review process for [212Pb] VMT-a-NET in addressing NETs. This status is conferred upon drugs that show promise in significantly enhancing the safety or effectiveness of treatment for serious medical conditions.

Who Are The Prominent Global Companies Shaping The Neuroendocrine Tumor Treatment Market?

Major companies operating in the neuroendocrine tumor treatment market include Pfizer Inc., F Hoffmann-La Roche AG, Abbvie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca, Takeda Pharmaceutical, Eli Lilly And Company, Amgen Inc., Merck & Co. Inc., Boehringer Ingelheim International GmbH, Servier, Teva Pharmaceutical Industries Ltd., Ipsen Pharma SAS, Exelixis Inc., Advanced Accelerator Applications SA, Hutchison Medipharma Ltd., Tarveda Therapeutics, GlycoMira Therapeutics Inc, AVEO Pharmaceuticals Inc., Progenics Pharmaceuticals Inc., Callisto Pharmaceuticals Pvt Ltd., Chiasma Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/neuroendocrine-tumor-treatment-global-market-report

How Does The Neuroendocrine Tumor Treatment Market Perform Across Key Geographic Regions?

North America was the largest region in the neuroendocrine tumor treatment market in 2024. The regions covered in the neuroendocrine tumor treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Neuroendocrine Tumor Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12248&type=smp

Browse Through More Reports Similar to the Global Neuroendocrine Tumor Treatment Market 2025, By The Business Research Company

Food Automation Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/food-automation-global-market-report

Sorting Machines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/sorting-machines-global-market-report

Filling Machines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/filling-machines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795